Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience

Zhou, Xin; Xia, Jun; Mao, Jingjue; Cheng, Feng; Qian, Xifeng; Guo, Hongwei

doi:10.1080/10245332.2015.1122259

Cited by 8 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These guidelines predominantly advocate for proteasome inhibitor-based therapies, as they offer superior response rates and improved survival outcomes, alongside the use of thalidomide, melphalan, lenalidomide, and cyclophosphamide [14]. In comparison to cost estimates from other countries, the monthly cost per patient for therapy medications alone in Singapore is higher than those reported in China [15], The Netherlands [16], and Germany [17], but considerably lower than the costs in the United States [18,19], which are nearly double. Several factors contribute to these variations.…”

Section: Discussionmentioning

confidence: 99%

Real‐world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore

Bayani,

Lin,

Ooi

et al. 2023

eJHaem

View full text Add to dashboard Cite

Multiple myeloma, a hematological malignancy, imposes a significant financial burden on healthcare systems. Health technology assessments (HTA) and economic evaluations play vital roles in reimbursement decisions and cost containment. This study aimed to explore healthcare utilization patterns and costs among myeloma patients in Singapore through a retrospective analysis of 605 patients treated at two cancer centers. Data encompassing demographics, treatment utilization, and billing were extracted from electronic records, and a cost analysis was performed from the perspective of the Singapore healthcare system. The results revealed common usage of immunomodulatory agents (52%) and proteasome inhibitors (37%), with bortezomib being the most frequently used targeted treatment. Treatment costs increased with disease progression, displaying variations depending on the therapeutic agent used. Notably, hospitalization costs due to adverse events were substantial, with pneumonia as the leading cause. This study highlights the high cost of myeloma therapy in Singapore, posing a financial burden for households. Findings may inform economic evaluations, evidence generation, reimbursement, and subsidy decisions. Leveraging real‐world data from electronic records provides valuable insights into local healthcare utilization patterns. Future studies may explore integrating billing databases with clinical repositories for a more comprehensive analysis, and consider limitations such as incomplete clinical information and potential selection bias.

show abstract

Section: Discussionmentioning

confidence: 99%

Real‐world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore

Bayani,

Lin,

Ooi

et al. 2023

eJHaem

View full text Add to dashboard Cite

show abstract

“…Several large studies examining the real-world costs of multiple myeloma in the US and China have been published in the last few years 6,8,9 , but recent European data (since 2013) reporting costs associated with novel agents are lacking. In particular, the relatively recent availability of pomalidomide and bendamustine has not been captured in the few published European studies [10][11][12][13][14] .…”

Section: Introductionmentioning

confidence: 99%

Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy

Gonzalez‐McQuire

Yong

Leleu³

et al. 2018

Journal of Medical Economics

View full text Add to dashboard Cite

Drug costs are the main contributor to total HRU costs associated with multiple myeloma. The duration of active treatment may influence the average total costs, as well as response, associated with a single line of therapy. Improved treatment outcomes, and reductions in unscheduled events and concomitant medication use may, therefore, reduce the overall HRU and related costs of care in multiple myeloma.

show abstract

“…After removing duplicates, we screened 226 records and assessed 138 full-text articles based on inclusion and exclusion criteria. Eventually, 92 pharmacoeconomic evaluations were included in the review and underwent data extraction (figure 1), detailed information on included studies can be found in online supplemental table 2 19–110…”

Section: Resultsmentioning

confidence: 99%

Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review

He,

Huang,

Chen

et al. 2023

BMJ Glob Health

View full text Add to dashboard Cite

BackgroundChina’s National Reimbursement Drug List (NRDL) has become the primary route for drug reimbursement in China. More recently, the authority has made pharmacoeconomic evaluation an integral part of the application for NRDL inclusion. The underlying financial conflict of interests (FCOI) of pharmacoeconomic evaluations, however, has the potential to influence evidence generated and thus subsequent decision-making yet remains poorly understood.MethodsWe searched for studies published between January 2012 and January 2022 on the 174 drugs added to the 2017–2020 NRDLs after successful negotiation. We categorised the study’s FCOI status into no funding, industry funding, non-profit funding and multiple fundings based on authors’ disclosure and assessed the reporting quality of included studies using the Consolidated Health Economic Evaluation Reporting Standards 2022 checklist. We compiled descriptive statistics of funding types and study outcomes using t-tests and χ2tests and conducted multivariate regression analysis.ResultsWe identified 378 records and our final sample included 92 pharmacoeconomic evaluations, among which 69.6% were conducted with at least one funding source. More than half (57.6%) of the evaluations reached favourable conclusions towards the intervention drug and 12.6% reached a dominant result of the intervention drug over the comparison from model simulation. The reporting quality of included studies ranged from 19 to 25 (on a scale of 28), with an average of 22.3. The statistical tests indicated that industry-funded studies were significantly more likely to conclude that the intervention therapy was economical (p<0.01) and had a significantly higher proportion of resulting target drug economically dominated the comparison drug (p<0.05).ConclusionThe study revealed that FCOI bias is common in published pharmacoeconomic evaluations conducted in Chinese settings and could significantly influence the study’s economical results and conclusions through various mechanisms. Multifaceted efforts are needed to improve transparency, comparability and reporting standardisation.

show abstract

Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience

Abstract: Real-world costs during treatment of RRMM varied greatly. Total costs during bortezomib-based regimens are significantly higher compared with non-bortezomib regimens. Further multi-center studies are needed to assess the cost-effectiveness of bortezomib for the treatment of RRMM in China.

Cited by 8 publications

References 14 publications

Real‐world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore

Real‐world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore

Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy

Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review

Contact Info

Product

Resources

About